A research team led by Prof. Wang Hongzhi at the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has found ...

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for ...

Process: Provide long-term appreciation through passive exposure to primarily large-cap US equities. Through O’Shaughnessy’s Canvas Custom Index platform, the investment process uses a risk-based ...

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations ...

There is a complex pathological relationship between diabetes and osteoporosis, two of the most common chronic diseases worldwide.

GLP-1 drugs male fertility research presented at ENDO 2026 finds Ozempic-class medications do not harm male hormones and may ...

Hyperglycemia can lead to excessive production of reactive oxygen species (ROS), contributing to diabetes and its complications, such as diabetic cardiomyopathy (DCM). This study aims to elucidate the ...

Palbociclib, ribociclib, and abemaciclib, which are FDA-approved CDK4/6 inhibitors, constitute the standard first-line treatment for advanced hormone receptor-positive (HR +) breast cancers. Although ...

Aggressive and therapy-resistant cancers present a significant challenge to treatment and are associated with poor patients’ survival. Identifying molecular pathways and compounds that target these ...

Good day, everyone. My name is Megan, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology Investor Call to discuss recent clinical data and the ...

The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional $60,000,000 aggregate principal amount of Convertible Notes, solely to cover ...

Eganelisib induced complete remissions and hematologic improvements as a single-agent via myeloid differentiation in a Phase 1 study in relapsed/refractory patients with myeloid malignancies (MDS/AML) ...